Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 10, 2024 07:00 ET | Source: Gritstone bio

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
June 13, 2024 07:00 ET | Source: Gritstone bio

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
June 04, 2024 16:05 ET | Source: Gritstone bio

Gritstone bio to Participate in Upcoming Investor and Scientific Conferences

EMERYVILLE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
May 09, 2024 16:05 ET | Source: Gritstone bio

Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates

-- Favorable progression-free survival (PFS) trend observed in preliminary data from the randomized Phase 2 study evaluating GRANITE (personalized neoantigen vaccine) in front-line metastatic,...
May 02, 2024 16:05 ET | Source: Gritstone bio

Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024

-- Conference call and webcast to begin at 4:30pm ET -- EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to...
April 30, 2024 07:00 ET | Source: Gritstone bio

Gritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024

-- IgG levels and neutralizing antibodies against variants of concern persisted for at least 12 months, consistent with previous findings -- -- Antigen-specific T cell responses increased in the...
April 29, 2024 07:00 ET | Source: Gritstone bio

Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors

EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
April 15, 2024 07:00 ET | Source: Gritstone bio

Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)

-- Paper details vaccine design optimization process of Gritstone’s “off-the-shelf” or shared neoantigen vaccine platform, SLATE -- -- Discovery of a novel immunodominance hierarchy of tumor...
April 08, 2024 08:00 ET | Source: Gritstone bio

Gritstone bio to Participate in Upcoming Investor and Scientific Conferences

EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
April 08, 2024 07:00 ET | Source: Gritstone bio

Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024

-- State-of-the-art neoantigen prediction platform (EDGE™) now predicts HLA Class I presentation of epitopes with >80% accuracy -- -- Newly developed EDGE-II model achieves superior predictive...